Search results for: Antibiotics
Filter search results
Spotlight on OHE: Innovation, Regulation and Antibiotics
30 September 2014
…the extensive resources necessary to develop new treatments in some disease areas, such as orphan diseases, and some therapeutic areas, such as antibiotics. For orphan diseases and antibiotics in particular, one…
Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechanism
30 March 2023
…years, the aim should be a full population-level economic evaluation, linked to QALY, and incorporating an antibiotic’s STEDI value. This consulting report, ‘Incentivising New Antibiotics: Designing a Value-Based Delinked Pull…
Antibiotics in Animal Husbandry
1 July 1969
…by intent. We first started to look at the “non-medical” use of antibiotics in animal husbandry some time ago, when there appeared to be a straightforward case for assessing what…
Spotlight on OHE: Beyond QALYs, Managed Entry Agreements, Business Models for Antibiotics, and the UK Market for Medicines.
12 April 2016
…incentives to accelerate clinical success for antibiotics. Jorge discussed the economic challenges around antibiotics, and whether there is a need for a new business model. He reviewed of the impact…
New Business Models for Antibiotics
22 April 2014, 11:00pm
Many stakeholders agree that the current business model for antibiotics is broken. Antibiotic innovation has slowed and many of the drugs on the market are losing effectiveness because of resistance….
HTA and Payment Mechanisms for New Drugs to Tackle AMR
23 September 2019
…of new antibiotics to the whole health system are needed to help match the size of the required payments to the value that they offer. The challenge with antibiotics assessment…
OHE’s AMR consultation response
21 November 2023
…antibiotics, reducing the ability of these antibiotics to treat infections. With increasing AMR there is an urgent need for novel antibiotics, but the current pipeline is underdeveloped, with few promising…
News Release: Fighting Superbugs
6 July 2011
…of new antibiotics in the pharmaceutical pipeline. Very few new classes of antibiotics have been discovered in the past decades. The two main reasons for this are the low returns…
New Drugs to Tackle Antimicrobial Resistance: Breaking the European Deadlock: Part 1 – Defining Objectives
25 May 2023
…antibiotics lose effectiveness over time as bacteria become resistant to them, but the market for new antibiotics is not commercially viable for reasons that are well documented, resulting in a…